Natera Inc (NTRA) shares climbed to an all‑time high of $343.94 on September 15, 2026, pushing the company’s market capitalization to approximately $49.4 billion. The stock’s one‑year total return stood at 98.5%.
In the second quarter, Natera reported revenue of about $753 million, exceeding the consensus forecast of $661.26 million by nearly 14%. The company said the result reflected accelerated growth, higher test volume and improved margins, prompting it to raise its full‑year revenue guidance.
Rothschild Redburn initiated coverage on Natera with a Buy rating and a price target of $385.00, citing the firm’s leadership in minimal residual disease testing through its Signatera tumor‑informed assay.
InvestingPro data indicated that the stock is currently trading above its fair value estimate, labeling it overvalued, and noted that 14 additional InvestingPro tips are available for further valuation and momentum analysis.
